Nascent Biotech (NBIO)

Executive Summary

Nascent Biotech is a Florida-based biotech company developing antibody and cytokine-based therapies for cancer treatment. Its lead candidate, Pritumumab, is a proprietary monoclonal antibody targeting a novel cancer antigen and has received FDA orphan drug designation. The company's strategy involves combining biomolecules into multi-targeted therapeutic 'cocktails' to mimic the body's natural immune response. While Pritumumab has shown promise in early studies, the company is still in preclinical or early clinical stages, with no approved products or revenue. The low valuation ($34k) reflects high risk and early stage. Success depends on securing funding, advancing clinical trials, and demonstrating efficacy. Key risks include limited pipeline, lack of partnerships, and regulatory hurdles.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1/2 clinical trial for Pritumumab40% success
• Q2 2026Additional orphan drug designation for new indication60% success
• Q1 2027Partnership or licensing agreement for Pritumumab25% success